Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
97 participants
OBSERVATIONAL
2024-02-14
2024-04-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quantification of Hepatic Steatosis With Different Ultrasound Frequency
NCT05855239
Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter
NCT06203548
Attenuation Imaging in Hepatic Steatosis
NCT05302258
Ultrasound Quantification of Liver Fat
NCT04523584
Usefulness of Ultrasound-derived Fat Fraction for Quantification of Hepatic Steatosis in Patients Suspected of MASLD
NCT06662851
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
All participants
Ultrasound attenuation imaging measurement
Ultrasound Attenuation imaging measurement
Participant to undergo conventional ultrasound scanning with attenuation measurement as well.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ultrasound Attenuation imaging measurement
Participant to undergo conventional ultrasound scanning with attenuation measurement as well.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* General Practitioner (GP) and Outpatients (OP) referral
* NAFLD, Unknown, Diabetes, Other metabolic disease
Exclusion Criteria
* Inpatients
* Known large liver masses
* Poor visualisation of the liver due to body type or anatomy.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hywel Dda Health Board
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bronglais Hospital
Aberystwyth, Ceredigion, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRAS 329847
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.